Company profile
PUMA BIOTECHNOLOGY, INC.
NASDAQ:PBYIBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NERLYNX | approved | $53.6MQ2 2026 | 0 | — |
| NERATINIB | phase3 | — | 33 | completed, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (36)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00398567 | phase1_2 | completed | 2007-04-04 | 2009-07-31 | Puma Biotechnology, Inc. | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer |
| NCT00445458 | phase1_2 | completed | 2007-09-11 | 2011-05-01 | Puma Biotechnology, Inc. | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer |
| NCT01128842 | phase1 | completed | 2010-04-01 | 2011-03-01 | Puma Biotechnology, Inc. | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor |
| NCT00397046 | phase1 | completed | 2006-11-01 | 2009-03-01 | Puma Biotechnology, Inc. | A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors |
| NCT07465757 | phase2 | recruiting | 2026-09-17 | 2028-03-31 | Puma Biotechnology, Inc. | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 208051 | 2017-07-17 | NDA | PUMA BIOTECHNOLOGY INC | |||||
Loading… | ||||||||